Switch theme
Sign up to access all valuation multiples
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology, and health tech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. The product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, and CB-01-33.
1997
322
LTM Revenue $233M
LTM EBITDA $130M
$936M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cosmo Pharmaceuticals has a last 12-month revenue (LTM) of $233M and a last 12-month EBITDA of $130M.
In the most recent fiscal year, Cosmo Pharmaceuticals achieved revenue of $320M and an EBITDA of $199M.
Cosmo Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cosmo Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $233M | XXX | $320M | XXX | XXX | XXX |
| Gross Profit | $183M | XXX | $296M | XXX | XXX | XXX |
| Gross Margin | 79% | XXX | 93% | XXX | XXX | XXX |
| EBITDA | $130M | XXX | $199M | XXX | XXX | XXX |
| EBITDA Margin | 56% | XXX | 62% | XXX | XXX | XXX |
| EBIT | $112M | XXX | $186M | XXX | XXX | XXX |
| EBIT Margin | 48% | XXX | 58% | XXX | XXX | XXX |
| Net Profit | $98.5M | XXX | $160M | XXX | XXX | XXX |
| Net Margin | 42% | XXX | 50% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Cosmo Pharmaceuticals's stock price is CHF 57 (or $68).
Cosmo Pharmaceuticals has current market cap of CHF 911M (or $1.1B), and EV of CHF 780M (or $936M).
See Cosmo Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $936M | $1.1B | XXX | XXX | XXX | XXX | $6.46 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Cosmo Pharmaceuticals has market cap of $1.1B and EV of $936M.
Cosmo Pharmaceuticals's trades at 2.9x EV/Revenue multiple, and 4.7x EV/EBITDA.
Equity research analysts estimate Cosmo Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cosmo Pharmaceuticals has a P/E ratio of 10.4x.
See valuation multiples for Cosmo Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV (current) | $936M | XXX | $936M | XXX | XXX | XXX |
| EV/Revenue | 3.8x | XXX | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | 6.7x | XXX | 4.7x | XXX | XXX | XXX |
| EV/EBIT | 7.8x | XXX | 5.0x | XXX | XXX | XXX |
| EV/Gross Profit | 4.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 10.4x | XXX | 6.8x | XXX | XXX | XXX |
| EV/FCF | 14.5x | XXX | 5.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCosmo Pharmaceuticals's last 12 month revenue growth is -29%
Cosmo Pharmaceuticals's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.3M for the same period.
Cosmo Pharmaceuticals's rule of 40 is -3% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cosmo Pharmaceuticals's rule of X is -17% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cosmo Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -29% | XXX | -23% | XXX | XXX | XXX |
| EBITDA Margin | 56% | XXX | 62% | XXX | XXX | XXX |
| EBITDA Growth | -42% | XXX | 58% | XXX | XXX | XXX |
| Rule of 40 | -3% | XXX | 33% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -17% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 34% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cosmo Pharmaceuticals acquired XXX companies to date.
Last acquisition by Cosmo Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Cosmo Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Cosmo Pharmaceuticals founded? | Cosmo Pharmaceuticals was founded in 1997. |
| Where is Cosmo Pharmaceuticals headquartered? | Cosmo Pharmaceuticals is headquartered in Switzerland. |
| How many employees does Cosmo Pharmaceuticals have? | As of today, Cosmo Pharmaceuticals has 322 employees. |
| Who is the CEO of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals's CEO is Mr. Giovanni Di Napoli. |
| Is Cosmo Pharmaceuticals publicy listed? | Yes, Cosmo Pharmaceuticals is a public company listed on SWX. |
| What is the stock symbol of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals trades under COPN ticker. |
| When did Cosmo Pharmaceuticals go public? | Cosmo Pharmaceuticals went public in 2007. |
| Who are competitors of Cosmo Pharmaceuticals? | Similar companies to Cosmo Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals's current market cap is $1.1B |
| What is the current revenue of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals's last 12 months revenue is $233M. |
| What is the current revenue growth of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals revenue growth (NTM/LTM) is -29%. |
| What is the current EV/Revenue multiple of Cosmo Pharmaceuticals? | Current revenue multiple of Cosmo Pharmaceuticals is 3.8x. |
| Is Cosmo Pharmaceuticals profitable? | Yes, Cosmo Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals's last 12 months EBITDA is $130M. |
| What is Cosmo Pharmaceuticals's EBITDA margin? | Cosmo Pharmaceuticals's last 12 months EBITDA margin is 56%. |
| What is the current EV/EBITDA multiple of Cosmo Pharmaceuticals? | Current EBITDA multiple of Cosmo Pharmaceuticals is 6.7x. |
| What is the current FCF of Cosmo Pharmaceuticals? | Cosmo Pharmaceuticals's last 12 months FCF is $60.2M. |
| What is Cosmo Pharmaceuticals's FCF margin? | Cosmo Pharmaceuticals's last 12 months FCF margin is 26%. |
| What is the current EV/FCF multiple of Cosmo Pharmaceuticals? | Current FCF multiple of Cosmo Pharmaceuticals is 14.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
